The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.

Ng VWW, Gerard G, Koh JJK, Loke KY, Lee YS, Ng NBH

Clinical obesity25 Jan 2024Cited by 16 (Europe PMC)

PMID38273176DOI10.1111/cob.12642PepBankPUB-38273176

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In patients with hypothalamic obesity, all patients treated with liraglutide had weight reduction after therapy.
In plain wordsIn people with hypothalamic obesity, all patients on liraglutide lost weight.
Peptide
Liraglutide
Outcome
DecreaseWeight reduction on liraglutide
Study
n = 5
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
All patients on liraglutide had weight reduction post-therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten studies comprising 5 case reports, 4 case series and 1 randomized-controlled trial included 54 patients (24 males, 30 females) with mean age of 25.2 (range 13-71) years with hypothalamic obesity who had received GLP-1 receptor agonists (exenatide = 48, liraglutide = 5 and dulaglutide = 1) over a…
Report a problemFND-3827317603

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with hypothalamic obesity, pooled GLP-1 receptor agonists (mostly exenatide) were linked to a mean weight reduction of 7.4 kg.
In plain wordsIn people with hypothalamic obesity, GLP-1 drugs as a group were linked to a mean weight loss of 7.4 kg.
Peptide
Liraglutide
Outcome
DecreaseWeight change, pooled GLP-1 receptor agonists
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean weight reduction
7.4 kg
pooled GLP-1 receptor agonists
Source sentences
Summary
Mean weight reduction of 7.4 (SD 7.92) kg was observed in patients in whom weight was reported
1 context sentence(design, population, supporting numbers)
Summary · context
Ten studies comprising 5 case reports, 4 case series and 1 randomized-controlled trial included 54 patients (24 males, 30 females) with mean age of 25.2 (range 13-71) years with hypothalamic obesity who had received GLP-1 receptor agonists (exenatide = 48, liraglutide = 5 and dulaglutide = 1) over a…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3827317601
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with hypothalamic obesity, 85.7% of patients on pooled GLP-1 receptor agonists lost weight.
In plain wordsIn people with hypothalamic obesity, 85.7% of those on GLP-1 drugs as a group lost weight.
Peptide
Liraglutide
Outcome
DecreaseProportion with weight loss, pooled GLP-1 receptor agonists
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Patients with weight loss
85.7%
pooled GLP-1 receptor agonists
Source sentences
Summary
with 85.7% of patients experiencing weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten studies comprising 5 case reports, 4 case series and 1 randomized-controlled trial included 54 patients (24 males, 30 females) with mean age of 25.2 (range 13-71) years with hypothalamic obesity who had received GLP-1 receptor agonists (exenatide = 48, liraglutide = 5 and dulaglutide = 1) over a…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3827317602
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with hypothalamic obesity, glycaemic control improved or was maintained in all patients measured on pooled GLP-1 receptor agonists.
In plain wordsIn people with hypothalamic obesity, blood sugar control improved or stayed the same on GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
MixedGlycaemic control, pooled GLP-1 receptor agonists
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Glycaemic control had either improved/maintained in all patients in whom this was measured.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten studies comprising 5 case reports, 4 case series and 1 randomized-controlled trial included 54 patients (24 males, 30 females) with mean age of 25.2 (range 13-71) years with hypothalamic obesity who had received GLP-1 receptor agonists (exenatide = 48, liraglutide = 5 and dulaglutide = 1) over a…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3827317604
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with hypothalamic obesity, nausea was one of the main side effects of pooled GLP-1 receptor agonists.
In plain wordsIn people with hypothalamic obesity, nausea was a main side effect of GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableNausea, pooled GLP-1 receptor agonists
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The main side effects of GLP-1 receptor agonist in individuals with hypothalamic obesity were nausea
1 context sentence(design, population, supporting numbers)
Summary · context
Ten studies comprising 5 case reports, 4 case series and 1 randomized-controlled trial included 54 patients (24 males, 30 females) with mean age of 25.2 (range 13-71) years with hypothalamic obesity who had received GLP-1 receptor agonists (exenatide = 48, liraglutide = 5 and dulaglutide = 1) over a…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3827317605
06HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with hypothalamic obesity, vomiting was one of the main side effects of pooled GLP-1 receptor agonists.
In plain wordsIn people with hypothalamic obesity, vomiting was a main side effect of GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableVomiting, pooled GLP-1 receptor agonists
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The main side effects of GLP-1 receptor agonist in individuals with hypothalamic obesity were nausea and vomiting
1 context sentence(design, population, supporting numbers)
Summary · context
Ten studies comprising 5 case reports, 4 case series and 1 randomized-controlled trial included 54 patients (24 males, 30 females) with mean age of 25.2 (range 13-71) years with hypothalamic obesity who had received GLP-1 receptor agonists (exenatide = 48, liraglutide = 5 and dulaglutide = 1) over a…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3827317606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.